Alpha Cognition Inc. Comm... (ACOG)
| Bid | 4.12 |
| Market Cap | 65.08M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -14.63M |
| EPS (ttm) | -2.02 |
| PE Ratio (ttm) | -2.07 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 4.24 |
| Volume | 59,083 |
| Avg. Volume (20D) | 75,963 |
| Open | 4.40 |
| Previous Close | 4.25 |
| Day's Range | 3.97 - 4.83 |
| 52-Week Range | 3.75 - 7.00 |
| Beta | 2.51 |
About ACOG
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treat...
Analyst Forecast
According to 1 analyst ratings, the average rating for ACOG stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 377.33% from the latest price.
Stock Forecasts
2 months ago · newsfilecorp.com
Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG)Dallas, Texas--(Newsfile Corp. - January 30, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners initiates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition In...